Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for four new medicines.
- diamorphine hydrochloride (Ayendi®) nasal spray was recommended for use in hospital emergency departments for the relief of severe pain caused by accidental injury in children and teenagers between 2 and 15 years of age.
- dupilumab (Dupixent®) was recommended to treat moderate to severe eczema in adolescents aged 12 to 17 years old.
- melatonin (Slenyto®) was not recommended to treat sleeping difficulties in children and adolescents aged 2 to 18 years old who have Autism Spectrum Disorder and/or Smith-Magenis syndrome (an inherited condition affecting the nerves and brain), when a healthy sleeping routine (such as a regular bedtime and soothing sleeping environment) has not worked well enough.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.